Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More

▤ Summary

—This week Xconomy published its latest annual preview of the upcoming year’s most important clinical results.Our two-part list, here and here , includes studies in Alzheimer’s disease, hemophilia, Duchenne muscular dystrophy, nonalcoholic steatohepatitis, cystic fibrosis, and more.—Proteostasis Therapeutics (NASDAQ: PTI ) delayed the release of the first data for an in-house three-drug cocktail for cystic fibrosis until early next year .—The FDA delayed a decision on whether to approve Merck’s pembrolizumab as a monotherapy for a majority of patients with newly diagnosed, advanced non-small cell lung cancer by three months.—A year after selling Ignyta to Roche for $1.7 billion, San Diego entrepreneur Jonathan … Next Page »

▦ Linked Companies